GILD
Gilead Sciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$151.00
−0.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 30.5B | 29.4B | 28.8B | 27.1B | 27.3B |
| Cost of Revenue | 6.2B | 6.2B | 6.3B | 6.5B | 5.7B |
| Gross Profit | 24.2B | 23.2B | 22.5B | 20.6B | 21.6B |
| Operating Expenses | |||||
| R&D Expense | 6.1B | 5.8B | 5.9B | 5.7B | 5.0B |
| SG&A Expense | 6.5B | 5.7B | 6.1B | 6.1B | 5.7B |
| General & Admin Expense | 1.7B | 2.2B | 2.6B | 2.8B | 4.9B |
| Selling & Marketing Expense | 2.8B | 3.5B | 3.5B | 3.3B | 778.0M |
| Other Expenses | 13.2B | — | 8.8B | 1.2B | 3.6B |
| Total Operating Expenses | 25.7B | 11.5B | 20.8B | 13.0B | 14.3B |
| Cost and Expenses | 31.9B | 17.7B | 27.1B | 19.5B | 20.0B |
| Operating Income (EBIT) | (1.5B) | 11.7B | 1.7B | 7.6B | 7.3B |
| Non-Operating | |||||
| Interest Income | 183.0M | 349.0M | 281.0M | 376.0M | 106.0M |
| Interest Expense | 998.0M | 1.0B | 977.0M | 944.0M | 935.0M |
| Net Interest Income | (815.0M) | (675.0M) | (696.0M) | (568.0M) | (829.0M) |
| Other Non-Op Income/Expense | (462.0M) | (1.9B) | (972.0M) | (746.0M) | (1.5B) |
| Non-Operating Income (excl Interest) | (67.0M) | 881.0M | (5.0M) | (198.0M) | 581.0M |
| EBT (Pre-Tax Income) | (2.0B) | 9.8B | 690.0M | 6.9B | 5.8B |
| Income Tax Expense | 1.3B | 1.3B | 211.0M | 1.2B | 1.2B |
| Bottom Line | |||||
| Net Income | (3.2B) | 8.5B | 480.0M | 5.7B | 4.6B |
| Earnings from Cont. Ops | (3.2B) | 8.5B | 479.0M | 5.6B | 4.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.2B) | 8.5B | 480.0M | 5.7B | 4.6B |
| Per Share | |||||
| Basic EPS | ($2.60) | $6.84 | $0.38 | $4.54 | $3.66 |
| Diluted EPS | ($2.67) | $6.78 | $0.38 | $4.50 | $3.64 |
| Revenue Per Share | $24.50 | $23.67 | $23.06 | $21.73 | $21.74 |
| Shares | |||||
| Basic Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.3B |
| Diluted Shares Outstanding | 1.2B | 1.3B | 1.3B | 1.3B | 1.3B |
| Profitability Metrics | |||||
| EBITDA | 636.0M | 13.6B | 4.4B | 10.5B | 8.9B |
| D&A | 2.1B | 2.8B | 2.8B | 2.7B | 2.1B |
| EBIT | (1.4B) | 10.8B | 1.7B | 7.8B | 6.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026